
EVGN Valuation
Evogene Ltd
- Overview
- Forecast
- Valuation
- Earnings
EVGN Relative Valuation
EVGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EVGN is overvalued; if below, it's undervalued.
Historical Valuation
Evogene Ltd (EVGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.64 is considered Undervalued compared with the five-year average of -2.31. The fair price of Evogene Ltd (EVGN) is between 9.63 to 10.10 according to relative valuation methord. Compared to the current price of 1.30 USD , Evogene Ltd is Undervalued By 86.5%.
Relative Value
Fair Zone
9.63-10.10
Current Price:1.30
86.5%
Undervalued
-0.60
PE
1Y
3Y
5Y
Trailing
Forward
-1.54
EV/EBITDA
Evogene Ltd. (EVGN) has a current EV/EBITDA of -1.54. The 5-year average EV/EBITDA is -0.38. The thresholds are as follows: Strongly Undervalued below -1.75, Undervalued between -1.75 and -1.07, Fairly Valued between 0.30 and -1.07, Overvalued between 0.30 and 0.99, and Strongly Overvalued above 0.99. The current Forward EV/EBITDA of -1.54 falls within the Undervalued range.
-1.19
EV/EBIT
Evogene Ltd. (EVGN) has a current EV/EBIT of -1.19. The 5-year average EV/EBIT is -1.34. The thresholds are as follows: Strongly Undervalued below -4.90, Undervalued between -4.90 and -3.12, Fairly Valued between 0.44 and -3.12, Overvalued between 0.44 and 2.22, and Strongly Overvalued above 2.22. The current Forward EV/EBIT of -1.19 falls within the Historic Trend Line -Fairly Valued range.
1.64
PS
Evogene Ltd. (EVGN) has a current PS of 1.64. The 5-year average PS is 52.44. The thresholds are as follows: Strongly Undervalued below -146.56, Undervalued between -146.56 and -47.06, Fairly Valued between 151.93 and -47.06, Overvalued between 151.93 and 251.43, and Strongly Overvalued above 251.43. The current Forward PS of 1.64 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Evogene Ltd. (EVGN) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.93. The thresholds are as follows: Strongly Undervalued below -8.23, Undervalued between -8.23 and -5.08, Fairly Valued between 1.22 and -5.08, Overvalued between 1.22 and 4.36, and Strongly Overvalued above 4.36. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Evogene Ltd. (EVGN) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.23. The thresholds are as follows: Strongly Undervalued below -3.54, Undervalued between -3.54 and -1.65, Fairly Valued between 2.11 and -1.65, Overvalued between 2.11 and 3.99, and Strongly Overvalued above 3.99. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Evogene Ltd (EVGN) has a current Price-to-Book (P/B) ratio of -2.40. Compared to its 3-year average P/B ratio of 1.31 , the current P/B ratio is approximately -283.21% higher. Relative to its 5-year average P/B ratio of 1.58, the current P/B ratio is about -251.59% higher. Evogene Ltd (EVGN) has a Forward Free Cash Flow (FCF) yield of approximately -185.08%. Compared to its 3-year average FCF yield of -112.82%, the current FCF yield is approximately 64.05% lower. Relative to its 5-year average FCF yield of -80.12% , the current FCF yield is about 131.02% lower.
-2.40
P/B
Median3y
1.31
Median5y
1.58
-185.15
FCF Yield
Median3y
-112.82
Median5y
-80.12
Competitors Valuation Multiple
The average P/S ratio for EVGN's competitors is 50.12, providing a benchmark for relative valuation. Evogene Ltd Corp (EVGN) exhibits a P/S ratio of 1.64, which is -96.73% above the industry average. Given its robust revenue growth of -41.67%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of EVGN decreased by 73.50% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -91.77 to -122.30.
The secondary factor is the Revenue Growth, contributed -41.67%to the performance.
Overall, the performance of EVGN in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch

KLTO
Klotho Neurosciences Inc
1.130
USD
-8.13%

SOGP
Sound Group Inc
5.270
USD
+2.53%

CJET
Chijet Motor Co Inc
2.650
USD
+1.15%

VRAX
Virax Biolabs Group Ltd
0.953
USD
-3.64%

CREV
Carbon Revolution PLC
5.420
USD
+10.39%

EONR
EON Resources Inc
0.318
USD
-4.52%

PMAX
Powell Max Ltd
0.410
USD
0.00%

INTJ
Intelligent Group Ltd
1.230
USD
+0.98%

ASNS
Actelis Networks Inc
0.524
USD
-1.32%
FAQ

Is Evogene Ltd (EVGN) currently overvalued or undervalued?
Evogene Ltd (EVGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.64 is considered Undervalued compared with the five-year average of -2.31. The fair price of Evogene Ltd (EVGN) is between 9.63 to 10.10 according to relative valuation methord. Compared to the current price of 1.30 USD , Evogene Ltd is Undervalued By 86.50% .

What is Evogene Ltd (EVGN) fair value?

How does EVGN's valuation metrics compare to the industry average?

What is the current P/B ratio for Evogene Ltd (EVGN) as of Jul 29 2025?

What is the current FCF Yield for Evogene Ltd (EVGN) as of Jul 29 2025?

What is the current Forward P/E ratio for Evogene Ltd (EVGN) as of Jul 29 2025?
